Rosemont Pharmaceuticals
Stacy Hopson is a highly experienced financial professional currently serving as Group Financial Controller at Rosemont Pharmaceuticals since November 2020, where responsibilities include integrating newly acquired US entities and overseeing financial processes and taxation. Previously, in the role of Financial Controller, Stacy led a team of seven, significantly improved year-end closing times, developed the group tax strategy, implemented SAP HANA, and managed all group treasury reporting. Prior experience includes Finance Manager at Xercise4Less, Senior Financial Accountant at Actavo, and various roles at Sagars Chartered Accountants. Stacy holds professional qualifications from ICAEW and CIOT, along with a BA (Hons) in Accounting and Finance from Durham University.
Rosemont Pharmaceuticals
At Rosemont our mission is to be a rapid developer, reliable manufacturer and global supplier of novel-delivery, patient-focused medicines. Our ambition has always been to support both patients with swallowing difficulties and the healthcare professionals who care for them. We are highly respected in the industry and have been instrumental in establishing best practice for the care of patients with swallowing difficulties. Rosemont advocate the use of liquid medication over manipulating solid dose medications and we have a range of educational materials designed for healthcare professionals which focuses on key patient groups and their medication management challenges. At Rosemont we have a portfolio of over 130 oral liquid medicines across a range of therapeutic areas including 70 licensed products. All of our products, both licensed and ‘specials’ are made to the same exacting standards under GMP. Our UK range also includes 9 products licensed for use with PEG/NG tubes. We are always seeking to expand our range of medicines and covert our ‘specials’ to licensed product wherever possible.